Diagnostic biomarkers

Anne Macgregor-Das; Michael S Goggins

doi:10.1007/978-1-4939-7193-0_56

Diagnostic biomarkers

Anne Macgregor-Das, Michael S Goggins

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Pancreatic adenocarcinoma is the fourth leading cause of cancer death and the most deadly of all solid malignancies. Current methods for the early detection and diagnosis of pancreatic adenocarcinoma are largely ineffective and not feasible for uncovering small, often treatable precursor lesions in the general population. The discovery of biomarkers that aid in the early detection of pancreatic cancer would help to improve outcomes in patients and be of invaluable clinical benefit. This review discusses important considerations for the development of diagnostic biomarkers and profiles the promising molecular markers that have been evaluated in recent years.

Original language	English (US)
Title of host publication	Pancreatic Cancer
Publisher	Springer New York
Pages	659-680
Number of pages	22
ISBN (Electronic)	9781493971930
ISBN (Print)	9781493971916
DOIs	https://doi.org/10.1007/978-1-4939-7193-0_56
State	Published - Apr 11 2018

Keywords

CA19-9
Circulating tumor DNA
Early detection
EUS (endoscopic ultrasound)
IPMN (intraductal papillary mucinous neoplasm)
KRAS
MCNs (mucinous cystic neoplasms)
Mutation
Pancreatic cancer
Pancreatic cyst
Pancreatic juice
PanIN (pancreatic intraepithelial neoplasia)

ASJC Scopus subject areas

Medicine (miscellaneous)

Access to Document

10.1007/978-1-4939-7193-0_56

Cite this

@inbook{59ba15270e25416db83cfb8f36e525bc,

title = "Diagnostic biomarkers",

abstract = "Pancreatic adenocarcinoma is the fourth leading cause of cancer death and the most deadly of all solid malignancies. Current methods for the early detection and diagnosis of pancreatic adenocarcinoma are largely ineffective and not feasible for uncovering small, often treatable precursor lesions in the general population. The discovery of biomarkers that aid in the early detection of pancreatic cancer would help to improve outcomes in patients and be of invaluable clinical benefit. This review discusses important considerations for the development of diagnostic biomarkers and profiles the promising molecular markers that have been evaluated in recent years.",

keywords = "CA19-9, Circulating tumor DNA, Early detection, EUS (endoscopic ultrasound), IPMN (intraductal papillary mucinous neoplasm), KRAS, MCNs (mucinous cystic neoplasms), Mutation, Pancreatic cancer, Pancreatic cyst, Pancreatic juice, PanIN (pancreatic intraepithelial neoplasia)",

author = "Anne Macgregor-Das and Goggins, {Michael S}",

year = "2018",

month = apr,

day = "11",

doi = "10.1007/978-1-4939-7193-0_56",

language = "English (US)",

isbn = "9781493971916",

pages = "659--680",

booktitle = "Pancreatic Cancer",

publisher = "Springer New York",

}

TY - CHAP

T1 - Diagnostic biomarkers

AU - Macgregor-Das, Anne

AU - Goggins, Michael S

PY - 2018/4/11

Y1 - 2018/4/11

N2 - Pancreatic adenocarcinoma is the fourth leading cause of cancer death and the most deadly of all solid malignancies. Current methods for the early detection and diagnosis of pancreatic adenocarcinoma are largely ineffective and not feasible for uncovering small, often treatable precursor lesions in the general population. The discovery of biomarkers that aid in the early detection of pancreatic cancer would help to improve outcomes in patients and be of invaluable clinical benefit. This review discusses important considerations for the development of diagnostic biomarkers and profiles the promising molecular markers that have been evaluated in recent years.

AB - Pancreatic adenocarcinoma is the fourth leading cause of cancer death and the most deadly of all solid malignancies. Current methods for the early detection and diagnosis of pancreatic adenocarcinoma are largely ineffective and not feasible for uncovering small, often treatable precursor lesions in the general population. The discovery of biomarkers that aid in the early detection of pancreatic cancer would help to improve outcomes in patients and be of invaluable clinical benefit. This review discusses important considerations for the development of diagnostic biomarkers and profiles the promising molecular markers that have been evaluated in recent years.

KW - CA19-9

KW - Circulating tumor DNA

KW - Early detection

KW - EUS (endoscopic ultrasound)

KW - IPMN (intraductal papillary mucinous neoplasm)

KW - KRAS

KW - MCNs (mucinous cystic neoplasms)

KW - Mutation

KW - Pancreatic cancer

KW - Pancreatic cyst

KW - Pancreatic juice

KW - PanIN (pancreatic intraepithelial neoplasia)

UR - http://www.scopus.com/inward/record.url?scp=85054042489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054042489&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-7193-0_56

DO - 10.1007/978-1-4939-7193-0_56

M3 - Chapter

AN - SCOPUS:85054042489

SN - 9781493971916

SP - 659

EP - 680

BT - Pancreatic Cancer

PB - Springer New York

ER -

Diagnostic biomarkers

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this